CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03375320
Title field or adapter rule: {'original_value': 'Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:22.016507+00:00
Published At: 2024-10-16T00:00:00+00:00
Record Updated At: 2026-10-26
Results Posted At: 2024-10-16
Source Retrieved At: 2026-10-31T22:17:25.750886+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Functioning Pancreatic Neuroendocrine Tumor", "Intermediate Grade Lung Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Tumor G1", "Locally Advanced Lung Neuroendocrine Neoplasm", "Locally Advanced Pancreatic Neuroendocrine Tumor", "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm", "Low Grade Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor", "Lung Neuroendocrine Tumor G2", "Metastatic Digestive System Neuroendocrine Neoplasm", "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Metastatic Pancreatic Neuroendocrine Neoplasm", "Metastatic Pancreatic Neuroendocrine Tumor", "Metastatic Thymus Neuroendocrine Neoplasm", "Neuroendocrine Neoplasm", "Neuroendocrine Tumor", "Neuroendocrine Tumor G2", "Non-Functioning Pancreatic Neuroendocrine Tumor", "Pancreatic Serotonin-Producing Neuroendocrine Tumor", "Thymus Neuroendocrine Tumor", "Unresectable Digestive System Neuroendocrine Neoplasm", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Pancreatic Neuroendocrine Neoplasm", "Unresectable Thymus Neuroendocrine Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-26", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT03375320"
protocolSection.identificationModule.officialTitle: "Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2024-10-16", "type": "ACTUAL"}

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Arm I (cabozantinib S-malate)', 'Arm II (placebo)'], 'description': 'Undergo blood and urine sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (cabozantinib S-malate)'], 'description': 'Given PO', 'name': 'Cabozantinib S-malate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (cabozantinib S-malate)', 'Arm II (placebo)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (cabozantinib S-malate)', 'Arm II (placebo)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm II (placebo)'], 'description': 'Given PO', 'name': 'Placebo Administration', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (cabozantinib S-malate)', 'Arm II (placebo)'], 'description': 'Ancillary studies', 'name': 'Quality-of-Life Assessment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (cabozantinib S-malate)', 'Arm II (placebo)'], 'description': 'Undergo x-ray', 'name': 'X-Ray Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.